AVIR (Atea Pharmaceuticals, Inc.) Stock Financials & Earnings

AVIRAtea Pharmaceuticals, Inc.

Mkt Cap$501M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$158M

EPS (TTM)-$1.94

Free Cash Flow (TTM)-$132M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	-$29M	-$42M
Q2 23	$0	-$16M	-$35M
Q3 23	$0	-$18M	-$41M
Q4 23	$0	-$104K	-$47M
Q1 24	$0	-$104K	-$70M
Q2 24	$0	-$104K	-$47M
Q3 24	$0	-$20M	-$37M
Q4 24	$0	-$104K	-$39M
Q1 25	$0	-$3M	-$39M
Q2 25	$0	-$2M	-$41M
Q3 25	$0	$0	-$46M
Q4 25	$0	-$104K	-$55M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$30M	$13M	—
Q2 23	$30M	$13M	—
Q3 23	$32M	$13M	—
Q4 23	$35M	$12M	—
Q1 24	$58M	$12M	—
Q2 24	$35M	$12M	—
Q3 24	$26M	$11M	—
Q4 24	$26M	—	$13M
Q1 25	$30M	$9M	—
Q2 25	$32M	$9M	—
Q3 25	$38M	$7M	—
Q4 25	$48M	—	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$183M	$437M	$620M
Q2 23	$214M	$394M	$608M
Q3 23	$138M	$457M	$595M
Q4 23	$144M	$434M	$578M
Q1 24	$161M	$381M	$541M
Q2 24	$243M	$259M	$502M
Q3 24	$98M	$384M	$483M
Q4 24	$65M	$390M	$455M
Q1 25	$119M	$306M	$425M
Q2 25	$88M	$292M	$380M
Q3 25	$77M	$252M	$329M
Q4 25	$96M	$206M	$302M

Shares Outstanding

Revenue Per Employee

Revenue / Employee